logo-loader
viewSativa Group PLC

Sativa welcomes the clarity of the FSA's guidelines on CBD products in food

The CBD wellness firm said it is committed to meeting the requirements of the FSA and is working on its application for FSA authorisation in conjunction with Stillcanna Inc.

Sativa Group PLC -

Sativa Group PLC (LON:SATI), the medicinal cannabis group, has welcomed the clarity of the regulatory framework concerning the use of cannabidiol (CBD) products in food.

On February 13 the Food Standards Agency (FSA) introduced a deadline of March 31, 2021, for the submission of valid “novel food” authorisations applications.

In Europe, a novel food is defined as an ingredient that had not been consumed en masse in the market prior to the creation of the novel foods catalogue in May 1997.

The CBD wellness firm said it is committed to meeting the requirements of the FSA and is working on its application in conjunction with Stillcanna Inc.

READ Sativa unveils takeover offer from Canadian group Stillcanna

Once a CBD product is authorised that authorisation applies to that product only, Sativa explained. This means using the same detailed production methods, for the exact same uses as described within the authorisation and using the same safety evidence base. Where a business buys CBD product from others, they must ensure these products are correctly authorised, and that they only use them in ways described in the authorisation. Sativa said it would continue to support white label customers with new food regulatory approved products.

The proposed combination of the Sativa and StillCanna will allow the merged company to offer a consistent seed to consumer supply from one single company, Sativa stressed. Sativa and StillCanna will be submitting a joint application for all combined products to provide a wide range within their portfolio of brands including Goodbody Botanicals and Goodbody Wellness for novel foods approval.

"We welcome and embrace the clarity of the regulatory framework as an important step to leading the development of a safe and legal market in the UK,” said Henry Lees-Buckley, the chief executive officer of Sativa.

“We are taking seriously the guidance from the FSA to reassure our customers and distribution partners that Sativa and StillCanna are at the forefront of building a sustainable CBD wellness industry. We have invested in our infrastructure to ensure that we are fully compliant with industry regulation for each step of the manufacturing process of our CBD products. By owning each step of that process we can ensure that compliance is maintained throughout,” he added.

Quick facts: Sativa Group PLC

Price: 3.15 GBX

AQSE:SATI
Market: AQSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sativa Group PLC signs LOI with Stillcanna to become part of the company

  Sativa Group PLC (AQSE: SATI) CEO Henry Lees-Buckley joined Steve Darling from Proactive to discuss the company signing a letter of intent with Stillcanna for the companies to come together as one. Lees-Buckley discusses the reason behind this move and what it does for them in...

on 11/6/20

2 min read